Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer | SpringerLink
Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study - The Lancet
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor | Business
Ocean Outlines Promise of SM-88 in Advanced Pancreatic Cancer
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design - ScienceDirect
Tyme Technologies Ceases SM-88 Clinical Trial Due To Drug Failure
Step Counts Correlated With QoL With SM-88 in Metastatic Pancreatic Cancer
Tyme Technologies (TYME.Q) Granted Additional US Patent Claims for Drug Delivery Method, Shares Climb 50% - Equity.Guru
TYME Inc. - TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer | SpringerLink
FDA Grants Orphan Drug Designation for SM-88 for Treatment of Pancreatic Cancer
Tyme Technologies Ceases SM-88 Clinical Trial Due To Drug Failure
Non-Hormonal Therapy for Recurrent Non-Metastatic Prostate Cancer
TYME - Major Catalysts Ahead: 1) SM-88 Poster At ASCO 2021, 2) Results Of Strategic Review June 10. Game-Changing Oncology Platform (NASDAQ:TYME) | Seeking Alpha
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 | Business Wire
TYME's Novel Metabolic-Based Cancer Therapy, SM-88,
SM-88 for Breast Cancer Clinical Trial | Power
TYME To Make An Impact
TYME's Novel Metabolic-Based Cancer Therapy, SM-88,
TYME Inc. - Data Publications - Scientific Presentations
TYME - Major Catalysts Ahead: 1) SM-88 Poster At ASCO 2021, 2) Results Of Strategic Review June 10. Game-Changing Oncology Platform (NASDAQ:TYME) | Seeking Alpha
SM-88 Moves Forward in HopES Sarcoma Trial
TYME Inc. - Our Science - SM-88 Overview
EX-99.1
TYME Technologies Inc - SM-88 Pancreatic Cancer Clinical Trial | Facebook
